Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting tags : Covid save search
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
Published: 2023-09-18 (Crawled : 20:00) - globenewswire.com
SXTP | $0.2506 -2.45% 130K
|
n/a
|
| O: -26.39%
H: 9.41%
C: 1.24%
fda pharma covid
BIONIK Laboratories InMotion® Robotics Technology Meets the Recovery Demands from an Increase of Stroke Patients Brought on by Severe Cases of COVID-19
Published: 2021-12-17 (Crawled : 14:00) - biospace.com/
BNKL | $0.1 -39.39% 1.8K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -1.55%
covid-19 inmotion ema technology covid stroke
General Meeting COVID-19 Update
Published: 2021-12-07 (Crawled : 12:00) - globenewswire.com
RYDAF | $33.69 -7.36% 2K
|
Energy Minerals
|
| O: 1.28%
H: 0.86%
C: 0.86%
covid covid-19
Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
Published: 2021-11-17 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
covid molnupiravir antiviral phase 3
COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial
Published: 2021-10-18 (Crawled : 07:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 1.3M
|
Health Technology
|
| O: 2.23%
H: 1.9%
C: -1.55%
covid cpg 1018 vaccine phase 3 trial
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
Published: 2021-09-22 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
covid expansion collaboration vaccine ceo
COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial
Published: 2021-09-22 (Crawled : 11:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 1.3M
|
Health Technology
|
| O: 6.33%
H: 30.76%
C: 18.92%
covid phase 2 biopharma phase 2/3 vaccine trial
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19
Published: 2021-09-13 (Crawled : 12:15) - globenewswire.com
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 3.05%
H: 1.38%
C: -3.69%
covid fda potential results vaccine
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)
Published: 2021-08-24 (Crawled : 12:00) - biospace.com/
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 11.21%
H: 1.41%
C: -8.06%
covid treatment fda potential results syndros
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
Published: 2021-07-23 (Crawled : 13:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: 0.53%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 2.15%
H: 1.85%
C: -1.77%
covid vaccine
Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
Published: 2021-07-23 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: 0.53%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 2.15%
H: 1.85%
C: -1.77%
covid vaccine
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
Published: 2021-07-19 (Crawled : 01:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: -2.51%
H: 0.83%
C: -0.86%
covid disease gene therapies trial gene therapy therapy
Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
Published: 2021-06-16 (Crawled : 23:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.08%
H: 0.56%
C: -0.81%
covid brazil
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Published: 2021-06-16 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.15%
H: 0.3%
C: -0.78%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.7%
H: 2.12%
C: -1.43%
covid casirivimab phase 3 trial sars-cov-2
Will COVID-19 Vaccines Need a Booster? CDC Will Meet to Decide
Published: 2021-05-27 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.11%
H: 0.54%
C: -0.27%
covid vaccine covid-19
Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June
Published: 2021-05-25 (Crawled : 13:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 1.46%
H: 3.11%
C: 1.62%
covid vaccine
Medical Affairs: Meeting the Challenges of COVID-19 and Omnichannel Engagement
Published: 2021-05-19 (Crawled : 18:00) - veeva.com
VEEV | $200.52 -0.29% -0.26% 540K
|
Technology Services
|
| O: -1.52%
H: 2.53%
C: 1.89%
covid covid-19
EURO Ressources holding of the annual ordinary general meeting of shareholders of May 19, 2021 in the framework of the Covid-19 pandemic
Published: 2021-05-04 (Crawled : 19:00) - globenewswire.com
IAG | News | $3.6 -2.97% 0.0% 6.9M
|
Non-Energy Minerals
|
| O: 0.66%
H: 3.62%
C: 3.62%
covid
Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic
Published: 2021-04-28 (Crawled : 06:00) - globenewswire.com
DBVT | $0.68 3.98% 2.6K
|
Health Technology
|
| O: 2.76%
H: 0.16%
C: -0.63%
covid
AAN Annual Meeting Highlights: Sleep Quality, Migraine, COVID-19 Interferon Treatment and More
Published: 2021-04-21 (Crawled : 15:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.48%
H: 0.59%
C: 0.4%
covid treatment migraine covid-19
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.